Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agenus Inc.
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.
The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.
- Contract Research, Toxicology Testing-CRO
- Drug Discovery Tools
- Other Names / Subsidiaries
- Antigenics Inc. Aronex Pharmaceuticals AgenTus Therapeutics, Inc. Agenus Royalty Fund, LLC Agenus Switzerland Inc. Agenus UK Limited 4-Antibody